← back to search

Jennifer Kimberly Lue

University of Pittsburgh · US
Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research, and Viral-associated cancers and disorders.
h-index
18
citations
1,628
works
159
NIH funding
primary concept
Medicine
email

Recent publications

Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma
Blood 2026cited by 3position: middledoi
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma
Blood Advances 2025cited by 8position: middledoi
Outcomes of <scp>CD19 CAR</scp>‐T therapy in central nervous system lymphoma: Insights from a multicentre experience
British Journal of Haematology 2025cited by 6position: middledoi
Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia
Blood 2025cited by 1position: middledoi
Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma
Blood 2024cited by 8position: middledoi
Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
Blood 2024cited by 8position: middledoi
Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
Blood 2024cited by 2position: middledoi
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Blood Advances 2023cited by 15position: middledoi
ENGINE: A Phase III Randomized Placebo Controlled Study of Enzastaurin/R-CHOP as Frontline Therapy in High-Risk Diffuse Large B-Cell Lymphoma Patients with the Genomic Biomarker DGM1
Future Oncology 2020cited by 20position: middledoi
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
Journal of Clinical Oncology 2019cited by 97position: middledoi
Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1
Blood 2019cited by 1position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jun Zhu · Nanjing Forestry University2 papers (2019–2020) · 2 papers (2019–2020)Roni Shouval · University of Minnesota Medical Center2 papers (2025–2025) · 2 papers (2025–2025) · 2 papers (2019–2020)Michael Scordo · Hospital Universitario Ramón y Cajal2 papers (2025–2025) · 2 papers (2019–2020)M. Lia Palomba · Memorial Sloan Kettering Cancer Center2 papers (2025–2025)Grzegorz S. Nowakowski · Mayo Clinic2 papers (2019–2020)Alfredo Rivas‐Delgado · Universitat de Barcelona2 papers (2025–2025)Yuqin Song · Zhengzhou University2 papers (2019–2020)Xiuhua Sun · South China Agricultural University2 papers (2019–2020) · 2 papers (2025–2025)Miguel‐Angel Perales · nLIGHT (United States)2 papers (2025–2025)Gilles Salles · Universidade Federal do Estado do Rio de Janeiro2 papers (2025–2025)Stephen D. Smith · Fred Hutch Cancer Center2 papers (2019–2020) · 2 papers (2019–2020)Yongping Song · First Affiliated Hospital of Zhengzhou University2 papers (2019–2020)Ling Li · Qingdao University2 papers (2019–2020)Joseph Maly · Norton Healthcare2 papers (2019–2020)